-
Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases
•
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche. The deal is aimed at developing intravenous genomic medicines for the treatment of specific neurodegenerative diseases. Sangamo has provided Genentech with an…
-
Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study
•
Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the Phase III AFFINE study for its gene therapy candidate, giroctocogene fitelparvovec, for the treatment of hemophilia A. With these results, Pfizer is now poised to prepare for regulatory submission for this one-time gene therapy, which…
